The company said it has decided to stop distributing its once-daily basal insulin Tresiba (insulin degludec) in Germany - Europe's largest pharmaceutical market - in the wake of a "negative ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that Novo Nordisk’s long-acting insulin, Tresiba (degludec), is approved for use in Europe.

“Without insulin, I die.” Novo Nordisk manufactures insulin products like NovoLog, Tresiba, Fiasp and Novolin. Novo Nordisk will also provide free insulin to qualifying patients below a ...

The QWINT-3 study compared efsitora with daily shots of Novo Nordisk’s NVO Tresiba (insulin degludec) for 78 weeks in T2D patients who have switched from daily basal insulin injections.

and now next-generation insulin analogs (Tresiba, Fiasp), which offer improved efficacy, safety, and convenience for patients. Tresiba also appears to offer greater dosing flexibility and less ...